Table 1
| Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
|---|---|---|---|---|---|
| BREAST | S1007 | Breast,Adj,N1,Endocrine+/-Chemo | 15-JAN-11 | 413 | 205 |
| S1207 | Brst,Adj,Endocrine+/-Everolimus | 03-SEP-13 | 458 | 239 | |
| S1416 | Brst, TNBC/BRCA, Cis+/- ABT-888 | 07-JUL-16 | 264 | 124 | |
| S1418 | Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 15-NOV-16 | 382 | 165 | |
| A011106 | Breast, Neoadj, ALTERNATE study | 15-FEB-14 | 249 | 115 | |
| A011401 | Breast, adj, Stage II/III HER2-, weight loss | 29-AUG-16 | 403 | 220 | |
| A011502 | Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 08-DEC-16 | 0 | 190 | |
| A221405 | Breast, ET interruption, Pregnancy Outcomes | 15-OCT-15 | 0 | 14 | |
| B55 | Brst, Adj Olaparib for BRCA,TNBC | 03-JUL-14 | 409 | 181 | |
| E1Z11 | Brst,Genetic Predictors of AIMSS | 10-MAY-13 | 259 | 86 | |
| E2112 | Brst,Adv,Exemestane+/-Entinostat | 02-JAN-14 | 289 | 167 | |
| NRGBR003 | Brst,Adj,TNBC,AC -> WP +/- Carbo | 22-JAN-15 | 422 | 216 | |
| CCD | S1415CD | TrACER CSF Standing Order Intervention for FN | 01-SEP-16 | 38 | 31 |
| S1417CD | Colorectal, Cost Cohort Study | 13-MAY-16 | 199 | 59 | |
| A011104 | Preoperative Breast MRI | 21-FEB-14 | 166 | 60 | |
| ERLYTX | S1609 | Rare Tumor, Comb Nivo/Ipi | 13-JAN-17 | 333 | 142 |
| A071102 | GBM, adj TMZ +/- Veliparib | 19-SEP-14 | 378 | 168 | |
| A071401 | Prog Meningiomas,SMO/AKT/NF2 Inhib | 06-AUG-15 | 248 | 104 | |
| ARST1321 | NonRhabdo STS,Pazopanib (PAZNTIS) | 16-MAY-14 | 244 | 117 | |
| EAY131 | MATCH | 12-AUG-15 | 441 | 236 | |
| GI | S1505 | Panc,Resect, Perioperative Chemo | 12-OCT-15 | 279 | 116 |
| S1513 | Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 | 01-SEP-16 | 302 | 143 | |
| A021501 | Adeno Panc,Borderline Resect,Chemo vs ChemoRT | 01-DEC-16 | 0 | 23 | |
| EA2133 | Anal, local recur/met, Cis+5FU vs Taxol/Carbo | 29-JAN-16 | 0 | 34 | |
| EA2142 | GI NEC, Adv G3, EP vs TMZ + CAP | 06-NOV-15 | 184 | 71 | |
| N1048 | Rectal,LocalAdv,ChemoRT+/-FOLFOX | 13-JAN-12 | 0 | 158 | |
| NRGGI002 | Rectal, Ph II, Sensitization using TNT | 12-OCT-16 | 289 | 121 | |
| R0848 | Panc, Adj, Erlotinib v ChemoRT | 01-MAR-14 | 0 | 152 | |
| GU | S1314 | Blad, COXEN Neoadj. Chemo + Cyst | 11-JUL-14 | 223 | 118 |
| S1500 | pRCC,Adv, Sunitinib vs MET inhib | 05-APR-16 | 196 | 87 | |
| S1602 | Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 07-FEB-17 | 136 | 61 | |
| S1605 | Blad, BCG-Unresponsive NMIBC, Atezolizumab | 07-FEB-17 | 133 | 58 | |
| A031102 | GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 01-JUL-15 | 56 | 33 | |
| EA8141 | UTUC, HG, Chemo then Surg | 27-JAN-15 | 153 | 75 | |
| NRGGU002 | Pros, RT + ADT After RP +/- Adj Docetaxel | 30-DEC-16 | 0 | 6 | |
| R0924 | Pros, NADT+WPRT vs. NADT+P&SV RT | 07-JUL-11 | 0 | 163 | |
| LEUK | S1312 | ALL, CD22+, REL/REF, Inotuzumab+CVP | 01-APR-14 | 4 | 5 |
| S1318 | ALL, Age 65+, Ph±, Blinatumomab | 12-JAN-15 | 176 | 73 | |
| E1910 | BCR-ABL-neg, B ALL, Blinatumomab | 23-DEC-13 | 167 | 92 | |
| E2906 | AML, Age 60+, Clo vs Dauno+Cy | 24-FEB-11 | 152 | 80 | |
| NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 62 | 27 | |
| LUNG | S1400 | SCCA,Adv, Biomarker Master | 15-JUN-14 | 432 | 223 |
| S1400G | HRRD: Talazoparib (BMN 673) | 07-FEB-17 | 432 | 222 | |
| S1400I | Non-Match: Nivo + Ipi vs Nivo | 18-DEC-15 | 433 | 223 | |
| S1403 | Adv,EGFR-mt,Afatinib+/-Cetuximab | 25-MAR-15 | 224 | 92 | |
| S1507 | NSCLC, Adv, Kras Mut, Trametinib + Docetaxel | 18-JUL-16 | 185 | 85 | |
| 8811 | NSCLC, Stage III,ChemoRT+ABT-888 | 02-JAN-13 | 133 | 54 | |
| A081105 | ALCHEMIST1, EGFR mut, Erlotinib | 02-JAN-14 | 0 | 248 | |
| A151216 | ALCHEMIST0 - screening | 06-FEB-14 | 455 | 250 | |
| C30610 | SCLC, Thoracic RT | 21-MAR-08 | 240 | 116 | |
| E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 458 | 257 | |
| EA5142 | ALCHEMIST3, Non-match, Nivolumab | 16-MAY-16 | 454 | 244 | |
| NRGCC003 | SCLC, PCI or HA-PCI | 07-DEC-15 | 322 | 143 | |
| R1306 | NSCLC,Adv,ALK/EGFR,TargetAgents | 04-NOV-13 | 162 | 70 | |
| LYMPH | S1608 | Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob | 10-AUG-17 | 0 | 16 |
| A051301 | ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 15-JUL-16 | 131 | 57 | |
| MELAN | S1320 | Adv, BRAF mut, Inter v Contin | 22-JUL-14 | 246 | 110 |
| S1404 | Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 | 15-OCT-15 | 392 | 172 | |
| S1512 | Melan, Adv, Desmoplastic, MK-3475 (pembro) | 20-OCT-16 | 73 | 31 | |
| S1616 | MELAN,, Adv, Ipilimumab ± Nivolumab | 17-JUL-17 | 0 | 34 | |
| EA6134 | Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 15-DEC-15 | 336 | 143 | |
| EA6141 | Melan, Avd, Nivolumab+Ipi ± Sargmostim | 01-MAR-16 | 299 | 123 | |
| MMYEL | E1A11 | MM, frontline, BLD vs CLD | 22-NOV-13 | 298 | 130 |
| OTHER | A091202 | Sarc, Efatutazone vs Placebo, Unresect ,Lipo | 02-SEP-14 | 53 | 30 |
| A091304 | Adv Sarc, MLN0128 v Pazopanib, PhI/II | 26-JAN-15 | 184 | 65 | |
| A091305 | HN, Adv, Thyroid PPAR agonist + Chemo | 01-SEP-14 | 117 | 36 | |
| A091401 | Sarc, | 18-JUN-15 | 195 | 77 | |
| A091404 | HN, AR+, Enzalutamide | 25-SEP-15 | 94 | 40 | |
| EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 0 | 8 | |
| EAQ152 | Communication & education in tumor profiling | 26-SEP-16 | 232 | 103 | |
| G0263 | Cerv, Stg I/IIA, adjv RT vs chemoRT | 12-APR-10 | 0 | 4 | |
| G0281 | Ovar, Recur/prog LG, IC chemo vs trametinib | 27-FEB-14 | 0 | 82 | |
| NRGBN001 | HN, novel vs. std chemoradiation + chemo | 28-AUG-15 | 0 | 109 | |
| NRGGY004 | Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo | 04-FEB-16 | 342 | 176 | |
| NRGGY005 | OVAR, Cedir vs Olaparib vs C+O vs Std of Care | 06-FEB-16 | 320 | 140 | |
| NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 190 | 68 | |
| R0724 | Cervical, Chem+RT +/- Adj. Chemo | 15-JAN-14 | 254 | 104 | |
| R0920 | HN, Adv, Postop IMRT ± Cetuximab | 24-DEC-13 | 331 | 152 | |
| R1216 | HN, Adv,Cis vs Dtx vs Dtx+Cetux | 18-MAR-13 | 275 | 121 | |
| PREV | S0820 | PACES: ColrecStg0-3 Blind DFMO/Sulindac | 01-MAR-13 | 305 | 110 |
| A211102 | Breast, Atypia via RPFNA, Metformin v Placebo | 01-FEB-15 | 25 | 10 | |
| A211201 | Breast Density, MA.32 companion | 22-AUG-12 | 25 | 15 | |
| EA1141 | Breast, Abbrev. MRI vs Digital Tomosynthesis | 02-SEP-16 | 0 | 8 | |
| SURV | S1316 | Compar. Effectiv. Trial for MBO | 09-MAR-15 | 13 | 18 |
| S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol | 15-SEP-17 | 0 | 5 | |
| E1Q11 | EROS: Reproductive Health in Cancer Survivors | 30-SEP-15 | 0 | 36 | |
| SXQOL | A221101 | Glioma, Nuvigil/Placebo Fatigue | 03-JUN-13 | 228 | 91 |
| A221102 | Brst,AI Arthralgia,Testosterone | 07-SEP-12 | 0 | 67 | |